LiquidiaLQDA
Fair Value
US$16.99
Share price22 Dec
US$79.21366.3% overvalued intrinsic discount
1Y536.22%
7D5.44%
Treprostinil Dependence And Litigation Risks Will Undermine Long Term Pulmonary Hypertension Prospects
AN
Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Published
22 Dec 25
Views
31
Not Invested